Cybin Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Cybin Inc. (CYBN).

If you purchased or held Cybin securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Cybin

Cybin is a biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company’s lead programs include CYB003, which targets major depressive disorder (MDD), and CYB004, aimed at generalized anxiety disorder (GAD).

Potential Concerns Under Investigation

Lawyers are reviewing whether Cybin may have made misleading statements or omitted key information regarding its clinical trial results, business prospects, and executive changes. The investigation centers on a series of events and disclosures that may have impacted investor value.

A major corrective event occurred on Sept. 2, 2025, when Cybin announced the immediate resignation of CEO Doug Drysdale. On that day, Cybin’s stock price dropped approximately 16.58%, falling from around $7.48 to $6.24 per share. This decline represented a loss of about $1.24 per share and erased roughly $25 million in market value in a single trading day, given the company’s outstanding share count of about 19.99 million.

Legal professionals could examine whether Cybin’s public statements about its lead programs, particularly CYB003 and CYB004, were accurate and supported by internal data. For instance, on June 26, 2024, Cybin announced “positive topline results” for CYB003, citing a mean 14-point reduction in depression scores and a 79% remission rate after two doses. Later, on Aug. 8, 2024, the company stated that CYB003 “has demonstrated a robust, sustained benefit, with 75% of patients…in remission four months after two doses (16mg)”. By early 2025, Cybin reported “100% of participants receiving two doses of 16mg were responders” and 71% were in remission. Attorneys may investigate whether these statements accurately reflected the underlying clinical data or if there were omissions regarding sample size, adverse outcomes, or other relevant information.

Securities attorneys could also be looking into Cybin’s forward-looking projections, such as the anticipated start of the CYB003 Phase 3 trial in “summer 2024,” and whether these projections were made with a reasonable basis (ir.cybin.com). While Cybin’s statements included standard risk disclaimers, lawyers may investigate whether any forward-looking statements were made with knowledge of contrary facts.

Your Rights and Next Steps

Investors who purchased Cybin securities and experienced financial losses may have important legal rights. This is currently an investigation, not a filed lawsuit. However, if evidence supports that Cybin or its executives made false or misleading statements, a class action lawsuit could be filed on behalf of affected investors.

Lawyers are ready to help investors understand their rights and options. Investors may be able to participate in any future class action to seek compensation for losses. It is important to gather records of Cybin stock purchases, sales, and account statements covering the class period. Legal professionals will review these details to determine eligibility and potential recovery.

If the investigation leads to a class action, eligible investors may be able to recover a portion of their losses. Participating in a class action does not require direct involvement in the litigation process; most investors simply submit a claim if a settlement or judgment is reached.

You May Be Entitled to Compensation

Securities investigations are time sensitive. If you purchased or held Cybin securities and suffered losses between June 26, 2024, and Sept. 2, 2025, you may be eligible to join any potential class action and seek compensation for your losses.

To protect your rights and learn more about your options, complete the form below to join the investigation.